The U.S. FDA Priority Review Voucher Read more
Counterfeit, Substandard and Generic Drugs: Distinct Definitions for Distinctly Different Problems Read more
Valganciclovir Patent Set Aside in India read MSF's statement
New MSF report shows Europe failing to pay fair share of TB research
MSF hosts malnutrition symposium in NY Read more
|
 |
|
 |
|
 |
Tuberculosis
|
Cough Up for TB ! MSF publishes new report revealing how Europe is failing to match up to the funding needs for new medical tools to beat tuberculosis Read more Press Release: Europe Failing to Respond to Global TB Threat
|
|
Reality Check on TB diagnostics MSF is holding a satellite meeting at the Union Conference in Paris to explore our and others' experience of diagnosing TB in the places where we work Read more
|
|
|
The Cambridge Declaration MSF has become a founder member of a new initiative, bringing together many actors in the field, that aims to drive forward clinical research into better treatment of drug-resistant TB. |
|
Long, toxic and barely effective: Patients with drug resistant TB must struggle with a two year treatment course, comprised of a complex combination of toxic drugs, that often have appalling side-effects. Click here to find out how MSF's patients in Uzbekistan cope |
|
|
Matching medical needs with new funding ideas: MSF brought together experts in fields of TB diagnostics development and health economists to brainstorm new ways of stimulating development of new diagnostic tools for TB Read a report of the meeting
|
|
Meet Monica Juma. She lives in Mathare, an impoverished community near Nairobi. She is co-infected with HIV and drug-resistant tuberculosis. Monica has to take care of her family while under treatment so she needs to come to the MSF clinic twice a day, everyday. Click here for slideshow |
|
New Drug Trials for Drug-Resistant TBIn a series of papers published by PLoS, international experts explain how innovative trials in patients with drug resistant TB could speed up delivery of new drugs, explore how to fill up the current TB pipeline with additional promising drugs and call for building of clinical trial capacity in developing countries. Paper on Randomized drug trials |
Access challenges for DR TB drugs
Getting hold of the drugs to treat our patients with drug resistant TB can be a real challenge: limited availability, irregular supplies and a lack of affordable generic drugs all increase the barriers to effective care Read more |
Dying for a Test
Martine Usdin, biologist with the MSF Access Campaign explains what needs to be done to improve TB diagnostics now and in the future. Click here Click here
|
MSF and Tuberculosis
|
